id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-N-2672-1737,FDA,FDA-2022-N-2672,FONSI for Amended EA for AAS,Other,Amendment,2024-10-02T04:00:00Z,2024,10,2024-10-02T04:00:00Z,,2024-10-02T15:08:05Z,,0,0,09000064867a673b
FDA-2022-N-2672-1738,FDA,FDA-2022-N-2672,Final Amended EA,Other,Amendment,2024-10-02T04:00:00Z,2024,10,2024-10-02T04:00:00Z,,2024-10-02T15:10:22Z,,0,0,09000064867a673d
FDA-2022-N-2672-1736,FDA,FDA-2022-N-2672,Draft Response to Public Comment on AAS Amended EA,Other,Response(s),2024-10-02T04:00:00Z,2024,10,2024-10-02T04:00:00Z,,2024-10-02T15:07:17Z,,0,0,09000064867a6739
FDA-2022-N-2672-1735,FDA,FDA-2022-N-2672,"Amended Environmental Assessment for Production of AquAdvantage Salmon at the Bay Fortune and Rollo
Bay Facilities on Prince Edward Island, Canada; Availability",Notice,Notice of Availability,2024-09-30T04:00:00Z,2024,9,,,2024-09-30T14:37:02Z,2024-22308,0,0,09000064867a0336